NASDAQ:NUVA - NuVasive Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding NuVasive, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $74.75 +0.98 (+1.33 %) (As of 12/6/2019 04:00 PM ET) Add Compare Today's Range$73.99Now: $74.75▼$75.0750-Day Range$64.88MA: $70.49▼$74.7552-Week Range$43.51Now: $74.75▼$75.07Volume386,474 shsAverage Volume549,506 shsMarket Capitalization$3.89 billionP/E Ratio33.52Dividend YieldN/ABeta1.17 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:NUVA Previous Symbol CUSIP67070410 CIK1142596 Webhttp://www.nuvasive.com/ Phone858-909-1800Debt Debt-to-Equity Ratio0.79 Current Ratio3.68 Quick Ratio2.08Price-To-Earnings Trailing P/E Ratio33.52 Forward P/E Ratio31.54 P/E Growth2.78 Sales & Book Value Annual Sales$1.10 billion Price / Sales3.53 Cash Flow$5.36 per share Price / Cash Flow13.94 Book Value$16.23 per share Price / Book4.61Profitability EPS (Most Recent Fiscal Year)$2.23 Net Income$12.47 million Net Margins4.15% Return on Equity14.93% Return on Assets7.17%Miscellaneous Employees2,600 Outstanding Shares52,046,000Market Cap$3.89 billion Next Earnings Date2/19/2020 (Estimated) OptionableOptionable Receive NUVA News and Ratings via Email Sign-up to receive the latest news and ratings for NUVA and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:NUVA Rates by TradingView NuVasive (NASDAQ:NUVA) Frequently Asked Questions What is NuVasive's stock symbol? NuVasive trades on the NASDAQ under the ticker symbol "NUVA." How were NuVasive's earnings last quarter? NuVasive, Inc. (NASDAQ:NUVA) posted its earnings results on Wednesday, October, 30th. The medical device company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.53 by $0.06. The medical device company earned $290.80 million during the quarter, compared to the consensus estimate of $283.75 million. NuVasive had a net margin of 4.15% and a return on equity of 14.93%. The firm's revenue for the quarter was up 7.2% on a year-over-year basis. During the same period last year, the firm posted $0.56 EPS. View NuVasive's Earnings History. When is NuVasive's next earnings date? NuVasive is scheduled to release their next quarterly earnings announcement on Wednesday, February 19th 2020. View Earnings Estimates for NuVasive. What guidance has NuVasive issued on next quarter's earnings? NuVasive issued an update on its FY19 earnings guidance on Wednesday, October, 30th. The company provided EPS guidance of $2.35-2.40 for the period, compared to the Thomson Reuters consensus estimate of $2.32. The company issued revenue guidance of $1.16 billion, compared to the consensus revenue estimate of prior $2.25-2.35. What price target have analysts set for NUVA? 12 Wall Street analysts have issued 1-year target prices for NuVasive's shares. Their forecasts range from $55.00 to $75.00. On average, they expect NuVasive's stock price to reach $66.82 in the next twelve months. This suggests that the stock has a possible downside of 10.6%. View Analyst Price Targets for NuVasive. What is the consensus analysts' recommendation for NuVasive? 12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for NuVasive. What are Wall Street analysts saying about NuVasive stock? Here are some recent quotes from research analysts about NuVasive stock: 1. According to Zacks Investment Research, "NuVasive exited the third quarter of 2019 on a promising note, with earnings and revenues beating estimates. We are encouraged to note that the company witnessed solid revenue growth across its U.S. Spinal Hardware business, driven by increased surgeon adoption of lateral single-position surgery and X360 system. Robust sales figures in some of the key international markets, especially in the EMEA region, buoy optimism. We are upbeat about the raised EPS guidance for 2019. Continued momentum across several recently-launched products within AMS portfolio is encouraging. In the past six months, NuVasive has outperformed its industry. On the flip side, the slight revenue decline within the U.S. Surgical Support and Biologics segments and contraction in adjusted operating margin were disappointing." (11/1/2019) 2. Cantor Fitzgerald analysts commented, ": We maintain our Neutral rating on NUVA, but raise our 12- month PT to $61 from $50 as NUVA’s performance justifies multiple expansion. NUVA reported 1Q revenue of $274.8MM (+5.9% organic), beating FactSet consensus by $5.6MM. 40bp benefit from one-time NCS collections and a faster-than-expected benefit from West Carrollton, GM (72.9%) and OM (14.9%) were higher than expectations, driving an EPS beat of $0.12. A number of favorable one-time items make determining the true underlying performance challenging." (5/2/2019) Has NuVasive been receiving favorable news coverage? Media headlines about NUVA stock have trended very positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. NuVasive earned a news sentiment score of 4.0 on InfoTrie's scale. They also assigned news coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for NuVasive. Who are some of NuVasive's key competitors? Some companies that are related to NuVasive include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Becton Dickinson and (BDX), Intuitive Surgical (ISRG), Boston Scientific (BSX), Edwards Lifesciences (EW), Baxter International (BAX), IDEXX Laboratories (IDXX), ResMed (RMD), DexCom (DXCM), Teleflex (TFX), Hologic (HOLX), Steris (STE) and Varian Medical Systems (VAR). What other stocks do shareholders of NuVasive own? Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include Incyte (INCY), BioMarin Pharmaceutical (BMRN), Puma Biotechnology (PBYI), Medivation (MDVN), Starbucks (SBUX), Celgene (CELG), Global Sources Ltd. (Bermuda) (GSOL), Alibaba Group (BABA), Intel (INTC) and Micron Technology (MU). Who are NuVasive's key executives? NuVasive's management team includes the folowing people: Mr. J. Christopher Barry, CEO & Director (Age 46)Mr. Matthew W. Link, Pres (Age 44)Dr. Peter M. Leddy, Exec. VP of People & Culture (Age 56)Mr. Rajesh J. Asarpota, Exec. VP & CFO (Age 52)Mr. Jereme Sylvain, Chief Accounting Officer (Age 39) Who are NuVasive's major shareholders? NuVasive's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Fisher Asset Management LLC (2.17%), Anchor Capital Advisors LLC (1.49%), Eagle Asset Management Inc. (1.49%), Stephens Investment Management Group LLC (1.19%), Sector Gamma AS (0.90%) and Carillon Tower Advisers Inc. (0.88%). Company insiders that own NuVasive stock include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Institutional Ownership Trends for NuVasive. Which institutional investors are selling NuVasive stock? NUVA stock was sold by a variety of institutional investors in the last quarter, including Anchor Capital Advisors LLC, Sector Gamma AS, Hussman Strategic Advisors Inc., Stephens Investment Management Group LLC, Fisher Asset Management LLC, DNB Asset Management AS, Stifel Financial Corp and Great West Life Assurance Co. Can. Company insiders that have sold NuVasive company stock in the last year include Gregory T Lucier, Matthew Link and Paul Mcclintock. View Insider Buying and Selling for NuVasive. Which institutional investors are buying NuVasive stock? NUVA stock was bought by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., TimesSquare Capital Management LLC, Copper Rock Capital Partners LLC, Eagle Asset Management Inc., Carillon Tower Advisers Inc., State of New Jersey Common Pension Fund D, Rice Hall James & Associates LLC and Squarepoint Ops LLC. View Insider Buying and Selling for NuVasive. How do I buy shares of NuVasive? Shares of NUVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is NuVasive's stock price today? One share of NUVA stock can currently be purchased for approximately $74.75. How big of a company is NuVasive? NuVasive has a market capitalization of $3.89 billion and generates $1.10 billion in revenue each year. The medical device company earns $12.47 million in net income (profit) each year or $2.23 on an earnings per share basis. NuVasive employs 2,600 workers across the globe.View Additional Information About NuVasive. What is NuVasive's official website? The official website for NuVasive is http://www.nuvasive.com/. How can I contact NuVasive? NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-909-1800 or via email at [email protected] MarketBeat Community Rating for NuVasive (NASDAQ NUVA)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 724 (Vote Outperform)Underperform Votes: 611 (Vote Underperform)Total Votes: 1,335MarketBeat's community ratings are surveys of what our community members think about NuVasive and other stocks. Vote "Outperform" if you believe NUVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NUVA will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/7/2019 by MarketBeat.com StaffFeatured Article: How do buyers and sellers choose a strike price?
